top of page

Our mission is to improve
the lives of the millions that
suffer from food allergies

find out more

Food allergies are on the rise,
with significant social, health, and economic impact

$25B

Each year is spent on healthcare costs related to food allergies and disorders

1 in every 13 children in

the United States is affected by food allergies

Every 3 minutes anaphylaxis sends someone to the E.R. 

Ukko uses its computational protein design platform to develop a pipeline of revolutionary therapeutics for life threatening allergies: modulating the immune system of allergic patients without triggering allergy

Leadership Team

Uri-Lopatin_ETB6420-1-scaled_edited_edit

URI LOPATIN
MD, CEO

YANAY OFRAN

PhD, Chairman & Co-founder 

ANAT BINUR

PhD, Sr. Advisor & Co-founder

Our Advisors

DanAdelman_2X.jpg

DR. DANIEL ADELMAN
Ukko's acting CMO; 
Former CMO of Aimmune Therapeutics, Alvine Pharmaceuticals & Sunesis; 
Advisory board at FARE

Tim-Garnett_edited.jpg

DR. TIM GARNETT 

Former CMO and SVP, Eli-Lily

DR. WESLEY A. BURKS

DR. WESLEY A. BURKS

Stuart Bondurant Distinguished Professor

Dean and CEO UNC School of Medicine and UNC Health

image1.jpg

DR. JAMES BAKER
Founding Director of
H. Weiser Food Allergy Center, Michigan University; CEO & CMO at FARE

dreskin_edited.jpg

PROF. STEPHEN DRESKIN 

Medical Director, Allergy and Clinical Immunology
Professor of Medicine and Immunology
Children’s Hospital Colorado

DR. LYNDA SCHNEIDER

PROF. LYNDA SCHNEIDER

Director, Allergy Program
Boston Children’s Hospital

Professor of Pediatrics, Harvard Medical School

DR. EDWIN KIM

DR. EDWIN KIM

Associate Professor, University of North Carolina; Director UNC Food Allergy Initiative

PROF. RAANAN SHAMIR

PROF. RAANAN SHAMIR

Chairman, Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center 

Interested in learning more about Ukko?

Follow our journey 

Thanks for submitting!

iStock-583972940_edited.jpg
Team
contact
stay informed
sequence_B-yellowtrans.png

We are building a clinically validated map of the molecular interaction between the allergen and the patient's immune system: unlocking critical knowledge about the biological mechanisms that drive human-food interactions

map_C-yellowtrans.png

Using this map, we then use our AI micro-engineering platform to design new versions of the allergen that do not trigger an allergic response but still re-educate the immune system to tolerate the allergen. This allows for a whole new approach to treating allergies

bottom of page